Review Article
Year: 2021 | Month: June | Volume: 8 | Issue: 6 | Pages: 193-198
DOI: https://doi.org/10.52403/ijrr.20210623
“Mucormycosis” The Emerging Global Threat – A Complete Review
A R Shabaraya1, Nypunya K2
1Professor & Head, Department of Pharmacy Practice, 2Student Pharm D, Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka-574143
Corresponding Author: Nypunya K
ABSTRACT
Mucormycosis is a life-threatening invasive fungal infection that affects people who are immunocompromised (haematological malignancies, solid organ transplantation, diabetes mellitus). Pulmonary, rhinocerebral, cutaneous, and disseminated infections are the most common. Controlling mucormycosis requires reversing the underlying problems. Treatment for mucormycosis also includes quick and vigorous surgery. Extensive surgical debridement of necrotic tissues is required. Finally, an antifungal treatment is required. High-dose liposomal amphotericin B (5 mg/kg/day) is the first-line treatment for mucormycosis. Antifungal chemotherapy has no set length; instead, it is determined by the remission of all related symptoms and results (usually 6-8 weeks). Posaconazole maintenance therapy/secondary prophylaxis should be recommended in patients who have a persistently weakened immune system.
Keywords: Mucormycosis, Diabetes mellitus, Liposomal Amphotericin B.
[PDF Full Text]